Methods and kits for predicting a response to an erythropoietic agent
First Claim
1. A method for predicting a response that a subject to be administered an erythropoietic agent would have to the administered erythropoietic agent, the method comprising:
- (a) providing a serum sample from the subject;
(b) measuring an amount in the sample of the peptide consisting of SEQ ID NO;
13;
(c) comparing the amount of the peptide in the sample to a control level of the peptide;
(d) predicting that the subject will have a good response to the erythropoietic agent when there is a measurable increase in the amount of the peptide consisting of SEQ ID NO;
13 in the sample as compared to the control level; and
(e) administering an amount of the erythropoietic agent to the subject based on the results of the predicting step (d), wherein a differing amount of the erythropoietic agent is administered when the subject is predicted to have a good response relative to the amount of the erythropoietic agent administered when the subject is not predicted to have a good response.
1 Assignment
0 Petitions
Accused Products
Abstract
Methods for predicting a response to an erythropoietic agent in a subject include providing a biological sample from the subject, and determining an amount in the sample of at least one peptide selected from the group consisting of SEQ ID NOS: 1-17. If there is a measurable difference in the amount of the at least one peptide in the sample, when compared to a control level of the same peptide, the subject is then predicted to have a good response or a poor response to the erythropoietic agent. Kits for predicting a response to an erythropoietic agent are further provided and include one or more antibodies, or fragments thereof, that specifically recognize a peptide of SEQ ID NOS: 1-17.
-
Citations
8 Claims
-
1. A method for predicting a response that a subject to be administered an erythropoietic agent would have to the administered erythropoietic agent, the method comprising:
-
(a) providing a serum sample from the subject; (b) measuring an amount in the sample of the peptide consisting of SEQ ID NO;
13;(c) comparing the amount of the peptide in the sample to a control level of the peptide; (d) predicting that the subject will have a good response to the erythropoietic agent when there is a measurable increase in the amount of the peptide consisting of SEQ ID NO;
13 in the sample as compared to the control level; and(e) administering an amount of the erythropoietic agent to the subject based on the results of the predicting step (d), wherein a differing amount of the erythropoietic agent is administered when the subject is predicted to have a good response relative to the amount of the erythropoietic agent administered when the subject is not predicted to have a good response. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
Specification